Learning Good Radiopharmacy Practice

Students will be introduced to the relevant technical requirements related to the set up of a nuclear pharmacy and the fundamental concepts of the cGRPP by EANM. The first component of the guideline is regarding personnel or human resource requirements.

Personnel is the most critical determinant of quality and safety in a radiopharmacy. While facilities, equipment, and systems provide the framework for control, it is the competence, behavior, and accountability of personnel that ultimately ensure compliance with current Good Radiopharmacy Practice (cGRPP). According to the standards set by the European Association of Nuclear Medicine, personnel requirements extend beyond staffing numbers—they encompass qualification, training, hygiene, responsibilities, and a culture of quality.

1. Defined Roles, Responsibilities, and Accountability

A compliant radiopharmacy must establish clearly defined organizational structures, ensuring that responsibilities are assigned, understood, and documented.

Key roles typically include:

• Responsible person / radiopharmacist.

• Production personnel.

• Quality assurance (QA) personnel.

• Quality control (QC) personnel.

• Radiation safety personnel.

Each role must have clearly defined authority, particularly in decision-making processes such as batch release, deviation management, and approval of procedures. Lack of role clarity can lead to gaps in accountability and increased operational risk.

2. Qualification, Training, and Competency

Personnel must be appropriately qualified through education, training, and experience to perform their assigned tasks.

A robust training system should include:

• Initial onboarding and role-specific training

• Ongoing competency assessments

• Training in aseptic techniques and contamination control

• Radiation safety and protection training

• Understanding of cGRPP and GMP principles

Competency must not be assumed—it must be demonstrated, documented, and periodically reassessed. Inadequately trained personnel represent one of the highest risks to product quality and patient safety.

3. Hygiene, Gowning, and Aseptic Behavior

Given the sterile and radioactive nature of radiopharmaceuticals, personnel must adhere to strict hygiene and gowning requirements.

This includes:

• Proper gowning procedures for classified cleanroom environments

• Personal hygiene standards to reduce contamination risks

• Behavioral discipline (e.g., minimizing movement, avoiding unnecessary contact)

Failure to comply with aseptic practices can directly result in microbial contamination, compromising product sterility and patient safety.

4. Personnel Health and Fitness to Work

Personnel must be in a condition that does not pose a risk to product quality or safety.

Considerations include:

• Health status and medical fitness

• Reporting of illnesses or conditions that may affect performance

• Restrictions on personnel with infections or open wounds

A structured system should be in place to assess and document fitness for work, particularly for those involved in aseptic operations.

5. Documentation and Training Records

All personnel-related activities must be fully documented, including:

• Training records and competency assessments

• Role descriptions and responsibilities

• Authorization for specific tasks (e.g., aseptic compounding, equipment operation)

These records provide evidence of compliance and are critical during regulatory inspections and audits.

Personnel in radiopharmacy are not simply operators—they are active guardians of product quality and patient safety. Their training, behavior, and decision-making directly influence compliance with cGRPP standards. A well-designed system can fail if personnel are not competent or engaged, whereas a strong, well-trained team can maintain control even in complex and high-risk environments.

Students will be introduced to the quality assurance concepts which influence the quality of a small scale radiopharmaceutical product.  Students will appreciate the requirement that a QA system must be place to make sure the end radiopharmaceutical product is safe and appropriate for its intended use.

Quality Assurance (QA) in radiopharmacy is a system-wide framework that ensures radiopharmaceuticals are consistently produced, controlled, and released in compliance with defined standards of quality, safety, and efficacy. In accordance with the principles outlined by the European Association of Nuclear Medicine under current Good Radiopharmacy Practice (cGRPP), QA is not a single activity but an integrated system of governance spanning personnel, processes, facilities, and documentation.

1. QA as a System of Control, Not Just Testing

QA in radiopharmacy is built on the principle that quality must be designed into the process, not inspected at the end.

This includes:

• Defined and validated procedures for all operations

• Controlled environments and qualified equipment

• Trained and competent personnel

• Standardized documentation systems

Given the short half-life of many radiopharmaceuticals, there is often limited time for extensive testing prior to release, making robust process control essential.

2. Documentation and Data Integrity

Documentation is the backbone of QA, ensuring traceability, reproducibility, and accountability. All activities must be recorded in real time and maintained in a manner that supports data integrity principles.

Key components include:

• Standard Operating Procedures (SOPs).

• Batch production and release records.

• Equipment logs and calibration records.

• Environmental monitoring data.

• Deviation and CAPA reports.

Poor documentation practices can invalidate otherwise compliant processes, leading to regulatory findings and loss of product credibility.

3. Release of Radiopharmaceuticals

QA oversight is critical in the release decision process, where each batch is evaluated against predefined specifications.

This involves:

• Verification of production records

• Review of quality control (QC) results (e.g., radiochemical purity, radionuclidic purity, sterility where applicable)

• Assessment of deviations or anomalies

  
  

4. Deviation Management and CAPA

No system operates without error. A mature QA system must include structured processes for:

• Identifying and documenting deviations.

• Investigating root causes.

• Implementing Corrective and Preventive Actions (CAPA).

• Monitoring effectiveness of actions.

Students must understand that uninvestigated deviations represent uncontrolled risk, particularly in a setting involving radioactive materials and patient administration.

Quality Assurance in radiopharmacy is a proactive, system-driven discipline that ensures every aspect of production—from raw materials to final product release—is controlled, documented, and continuously improved. In the context of cGRPP, QA is not optional; it is the foundation upon which safe and effective radiopharmaceutical practice is built.

Students will be introduced to the minimal requirements of the facility and equipment in a nuclear pharmacy.

The safe and compliant operation of a radiopharmacy relies fundamentally on the design, control, and maintenance of its facilities and equipment systems. In alignment with European Association of Nuclear Medicine current Good Radiopharmacy Practice (cGRPP) guidelines, these elements are not merely infrastructural—they are critical control points that directly impact product quality, radiation safety, and regulatory compliance.

1. Facilities as a Controlled Environment

Radiopharmacy facilities must be designed to ensure both sterility and radiation protection, creating a dual-control environment that distinguishes them from conventional pharmaceutical settings.

This includes:

• Controlled cleanroom classifications (e.g., Grade A/B/C environments).

• Directional airflow and pressure differentials.

• Segregation of “hot” (radioactive) and “cold” (non-radioactive) zones.

• Shielding requirements to protect personnel and the environment.

The facility layout should facilitate unidirectional workflow, minimizing cross-contamination risks while maintaining operational efficiency. Any compromise in facility design—such as poor airflow control or inadequate zoning—can lead to contamination, product failure, or radiation exposure incidents.

2. Critical Equipment and Functional Integrity

Equipment used in radiopharmacy—such as dose calibrators, isolators, laminar airflow cabinets, and synthesis modules—must be fit for purpose, qualified, and routinely maintained.

Key expectations include:

• Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) for all critical equipment.

• Routine calibration (e.g., dose calibrators for activity measurement).

• Preventive maintenance schedules aligned with manufacturer and regulatory expectations.

• Real-time monitoring systems for critical parameters (temperature, pressure, radiation levels).

  
  

3. Environmental Monitoring and Control

A compliant radiopharmacy must implement a robust environmental monitoring program, which includes:

• Particulate monitoring (airborne particles).

• Microbiological monitoring (surface and air sampling).

• Radiation contamination checks.

• Temperature, humidity, and pressure monitoring.

These parameters must be monitored over time to detect deviations and ensure the facility remains within validated operational limits. Failure to control environmental conditions can result in loss of sterility assurance or regulatory non-compliance.

4. Cleaning, Decontamination, and Housekeeping

Cleaning in a radiopharmacy is not only about maintaining sterility but also about managing radioactive contamination.

Effective systems must define:

• Cleaning agents and their rotation.

• Frequency and location-specific cleaning schedules.

• Responsibilities and documentation requirements.

• Decontamination procedures for radioactive spills or residues.

Improper cleaning practices can lead to cumulative contamination, impacting both product quality and occupational safety.

5. Documentation, Traceability, and Compliance

All facility and equipment activities must be fully documented and traceable, including:

• Maintenance and calibration records.

• Environmental monitoring logs.

• Cleaning records.

• Deviations and corrective actions (CAPA).

Documentation serves as evidence of control and is essential for audit readiness, particularly under regulatory inspections aligned with GMP principles.

Facilities and equipment in radiopharmacy are not passive assets—they are active quality systems. Their design, qualification, monitoring, and maintenance form the backbone of compliance with cGRPP standards. A well-controlled environment ensures that radiopharmaceuticals are consistently produced with the required quality, safety, and efficacy, ultimately safeguarding patient outcomes.

Students will be introduced to the critical requirements during the production of small scale radiopharmaceuticals in a nuclear pharmacy.

Production of radiopharmaceuticals is a time-critical process that directly impacts patient safety. Unlike conventional pharmaceutical manufacturing, radiopharmaceuticals are often prepared for immediate clinical use, with limited opportunity for extensive end-product testing. Therefore, in alignment with the standards of the European Association of Nuclear Medicine current Good Radiopharmacy Practice (cGRPP), production must be governed by strict process control, validated procedures, and disciplined execution.

1. Controlled and Standardized Production Processes

All production activities must be performed according to approved and validated Standard Operating Procedures (SOPs). These procedures define:

• Step-by-step preparation methods.

• Critical process parameters (e.g., temperature, time, activity levels).

• Materials and reagents to be used.

• In-process controls and acceptance criteria.

Standardization ensures reproducibility and consistency across batches. Any deviation from established procedures introduces variability and potential risk to product quality.

2. Aseptic Processing and Contamination Control

Many radiopharmaceuticals are administered intravenously and must be sterile and free from contamination. Production must therefore be conducted under controlled aseptic conditions, including:

• Use of qualified cleanroom environments or isolators.

• Strict adherence to aseptic techniques.

• Minimization of manual interventions.

• Environmental monitoring during production.

Inadequate aseptic control can lead to microbial contamination, which may not be immediately detectable before patient administration.

3. Material Control and Traceability

All materials used in production—including radionuclides, kits, reagents, and consumables must be:

• Approved and sourced from qualified suppliers.

• Checked for integrity and expiry prior to use.

• Traceable to each production batch.

  
  

4. In-Process Controls and Critical Parameters

Given the limited time for final testing, in-process controls are essential to ensure the product meets quality requirements during production.

Examples include:

• Monitoring reaction conditions (e.g., temperature, pH, time).

• Visual inspection of product appearance.

• Verification of activity levels.

These controls act as real-time checkpoints, allowing immediate detection and correction of issues before product release.

5. Prevention of Cross-Contamination and Mix-Ups

Radiopharmacy production often involves multiple radionuclides and products within the same facility. Strict measures must be implemented to prevent cross-contamination between products and mix-ups of materials, labels, or batches

This includes:

• Physical or temporal segregation of processes.

• Clear labeling and identification systems.

• Line clearance procedures before and after production.

  
  

6. Documentation and Batch Records

Every production activity must be fully documented in real time, forming a complete and traceable batch record.

This includes:

• Materials used and their batch numbers.

• Process steps and parameters.

• Personnel involved.

• In-process checks and observations.

• Deviations or anomalies.

Batch records provide the evidence required for quality assurance review and product release, as well as traceability in the event of investigations.

Production in radiopharmacy is a precision-driven process where quality must be built into every step.

Students will be introduced to the quality aspects of the Good Radiopharmacy Practice.

Quality Control (QC) of radiopharmaceuticals is a critical safeguard that ensures any radiopharmaceutical administered to patients meets predefined standards of identity, purity, safety, and performance. Within the framework of current Good Radiopharmacy Practice (cGRPP) established by the European Association of Nuclear Medicine, QC is not an isolated laboratory activity—it is an integral component closely linked to production, quality assurance, and patient outcomes.

1. Purpose and Scope of QC in Radiopharmacy

QC is designed to verify that each batch complies with specifications before administration. However, due to the short half-lives of many radiopharmaceuticals, QC must be:

• Rapid and reliable.

• Scientifically validated.

• Performed using qualified methods and equipment.

Unlike conventional pharmaceuticals, where full QC results are available prior to release, radiopharmacy QC often operates under time constraints, requiring a balance between speed and analytical rigor.

2. Key Quality Attributes and Tests

QC testing must address the critical quality attributes of radiopharmaceuticals, including:

• Radiochemical purity (RCP).

• Radionuclidic purity.

• Chemical purity.

• pH measurement.

• Sterility.

• Visual inspection.

Each test contributes to a holistic assessment of product quality, and failure in any parameter may compromise patient safety.

4. Documentation, Data Integrity, and Review

All QC activities must be fully documented and traceable, ensuring compliance with data integrity principles.

This includes:

• Raw data records (e.g., chromatograms, spectra).

• Calculations and results.

• Analyst identification and timestamps.

• Review and approval by authorized personnel.

  
  

5. Handling Out-of-Specification (OOS) Results

When QC results fall outside predefined specifications:

• The result must be immediately investigated.

• The batch must be withheld or rejected as appropriate.

• Root cause analysis and CAPA must be initiated.

Ignoring or inadequately investigating OOS results introduces significant risk to patient safety and regulatory compliance.

QC procedures must be scientifically robust, operationally efficient, and fully integrated with QA and production systems. Ultimately, QC serves as a critical checkpoint in ensuring that radiopharmaceuticals are safe, effective, and fit for clinical use.

Students will be introduced to the documentation aspects of the Good Radiopharmacy Practice.

Documentation in radiopharmacy is not an administrative task—it is a critical control system that ensures traceability, accountability, and regulatory compliance across all aspects of radiopharmaceutical practice. Under the current Good Radiopharmacy Practice (cGRPP) framework established by the European Association of Nuclear Medicine, documentation provides objective evidence that processes are performed as intended and that products meet required standards of quality, safety, and efficacy.

1. Documentation as a Core Quality System

In radiopharmacy, where products are often prepared and administered within short timeframes, documentation serves as:

• Proof of compliance with established procedures.

• A mechanism for traceability of materials, processes, and personnel.

• A foundation for batch release decisions.

• Evidence during audits and regulatory inspections.

If an activity is not documented, it is considered not performed. This principle underscores the central role of documentation in ensuring control and accountability.

2. Types of Documentation in Radiopharmacy

A comprehensive documentation system must cover all operational and quality aspects, including:

• Standard Operating Procedures (SOPs)

• Define how processes are to be performed consistently

• Batch production records

• Capture all details of each preparation, including materials, steps, and personnel

• Quality control records

• Document analytical results and test conditions

• Equipment logs

• Record calibration, maintenance, and usage

• Environmental monitoring records

• Track cleanroom and facility conditions

• Training records

• Demonstrate personnel competency

• Deviation and CAPA Reports

• Capture and manage non-conformances

Documentation in radiopharmacy is a fundamental pillar of quality assurance, ensuring that all activities are controlled, traceable, and verifiable. Documentation is not optional—it is the evidence of quality itself. A robust documentation system enables transparency, supports decision-making, and ultimately safeguards patient safety.

Students will be introduced to the importance of records in the nuclear pharmacy.

Within radiopharmacy practice, records are the living evidence of operations performed. While documents (e.g., SOPs) define what should be done, records capture what was actually done. Under the current Good Radiopharmacy Practice (cGRPP) principles outlined by the European Association of Nuclear Medicine, records are essential for traceability, accountability, and regulatory compliance, forming the factual basis for quality assurance and patient safety decisions.

1. Records as Objective Evidence of Compliance

Records provide verifiable, real-time evidence that processes have been executed in accordance with approved procedures.

They are critical for:

• Confirming that production and QC activities were performed correctly.

• Supporting batch release decisions.

• Enabling traceability of materials, personnel, and processes.

• Facilitating investigations, audits, and regulatory inspections.

In regulatory terms, if it is not recorded, it is assumed not to have occurred, regardless of actual practice.

2. Control, Storage, and Retention of Records

Records must be:

• Protected from loss, damage, or unauthorized access.

• Stored in a secure and organized manner.

• Retained for defined periods in accordance with regulatory requirements.

Whether paper-based or electronic, systems must ensure that records remain accessible, retrievable, and intact throughout their lifecycle.

In radiopharmacy, records are not passive paperwork—they are the factual backbone of the quality system. They provide the evidence needed to demonstrate that processes are controlled, products are safe, and regulatory requirements are met. Under cGRPP principles, robust record-keeping is essential to ensure transparency, traceability, and patient safety.

Students will be introduced to the final stage of radiopharmaceutical handling—encompassing finished product controls, distribution, and complaints management—represents the last critical safeguard before and after patient administration. This phase ensures that only products meeting predefined specifications are released, transported safely, and monitored throughout their lifecycle, including post-administration feedback.

1. Finished Product Controls: Verification Before Release

Finished product controls are designed to confirm that each batch meets all quality requirements prior to administration.

This includes:

• Review of batch production records for completeness and compliance.

• Verification of quality control (QC) results, such as radiochemical purity, radionuclidic identity, and activity levels.

• Confirmation that critical parameters (e.g., pH, appearance) meet specifications.

• Assessment of any deviations or anomalies during production.

Given the short half-life of many radiopharmaceuticals, some tests (e.g., sterility) may be completed after release. Therefore, the release decision relies on a combination of immediate QC data and validated process assurance.

A failure in finished product control can result in unsafe or substandard products reaching patients, making this step a key decision point in the quality system.

2. Dispensing and Distribution: Maintaining Quality Beyond Production

Once released, radiopharmaceuticals must be distributed under conditions that preserve their quality, safety, and identity.

Key considerations include:

• Time-sensitive delivery, accounting for radioactive decay.

• Maintenance of appropriate environmental conditions (e.g., temperature control).

• Radiation shielding and compliance with transport regulations.

• Secure labeling and documentation to prevent mix-ups.

Distribution systems must ensure traceability, allowing each product to be tracked from production to administration.

3. Complaints Management: Post-Distribution Quality Feedback

Complaints provide valuable information on product performance and system weaknesses.

A compliant system must ensure:

• All complaints are documented, assessed, and investigated.

• Root causes are identified.

• Corrective and Preventive Actions (CAPA) are implemented.

Complaints may relate to:

• Product quality (e.g., unexpected appearance, reduced efficacy).

• Packaging or labeling issues.

• Delivery or handling concerns.

Ignoring or inadequately investigating complaints can result in repeated failures and regulatory non-compliance.

Finished product control, distribution, and complaints management are not isolated activities—they are integrated within the overall quality system.

They interact with:

• Production (process control and batch records).

• Quality Control (analytical results).

• Quality Assurance (release decisions and oversight).

• CAPA systems (continuous improvement).

A robust system in these areas is essential for protecting patients, maintaining regulatory compliance, and enabling continuous improvement.